Oric Pharmaceuticals Inc (ORIC) Annual Balance Sheets

Annual · GAAP · USD millions
Access ORIC quarterly Balance Sheets →
Observing balance sheet movements over recent quarters helps explain how Oric Pharmaceuticals Inc adapts its asset base and funding mix.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Assets
Cash & cash equivalent45.67
Available-for-sale Securities, Debt Securities, Current MA235.82
Cash & Short-term Investments280.00
Prepaid Expense And Other Assets Current6.98
Total Current Assets288.47
Equipment/Property/Plant Net2.42
Long-term investments110.76
Other Assets, Noncurrent118.01
Total Assets408.89
Liabilities
Accounts Payable, Current AC3.82
Accrued Liabilities, Current AC16.59
Other Liabilities, Current0.00
Total Current Liabilities20.42
Total Long-term Debt0.00
Other liabilities, Noncurrent4.11
Total Liabilities24.53
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock1,075.81
Retained Earnings / Accumulated Deficit-692.24
Other Equity0.79
Common Stockholder's Equity384.36
Total Stockholder's Equity384.36
Liabilities & Stockholder's Equity408.89
4 historic quarters locked

Sign in to unlock the full Oric Pharmaceuticals Inc balance sheet history.

About Oric Pharmaceuticals Inc Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 23, 2026
  • Source: oric-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-064005

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.